Lee A. Albacker

8.8k citations

89 papers · 3.7k indexed · 3 hit papers · h-index 21

Immunology top 1%
Oncology top 2%
Surgery top 5%
Pulmonary and Respiratory Medicine top 5%
Molecular Biology

Co-authors: Dale T. Umetsu Rosemarie H. DeKruyff Ya‐Jen Chang Hye Young Kim Gordon J. Freeman Andrew N. J. McKenzie Dirk E. Smith Yvette Latchman
Topics: Cancer Genomics and Diagnostics (38 papers)Lung Cancer Treatments and Mutations (22 papers)Cancer Immunotherapy and Biomarkers (18 papers)
Cited by: Immunology Oncology Cancer Research
Journals: Journal of Biological Chemistry Nature Medicine The Journal of Experimental Medicine
Partner nations: United States Italy United Kingdom

In The Last Decade

Lee A. Albacker

80 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tissue expression of PD-L1 mediates peripheral T cell tolerance

2006 1.0k citations Mary Keir, Spencer C. Liang et al. The Journal of Experimental Medicine profile →
Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity

2011 640 citations Ya‐Jen Chang, Hye Young Kim et al. Nature Immunology profile →
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers

2019 386 citations Mark Yarchoan, Lee A. Albacker et al. JCI Insight profile →

Peers

Countries citing papers authored by Lee A. Albacker

Since Specialization

Citations

This map shows the geographic impact of Lee A. Albacker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lee A. Albacker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lee A. Albacker more than expected).

Fields of papers citing papers by Lee A. Albacker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lee A. Albacker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lee A. Albacker. The network helps show where Lee A. Albacker may publish in the future.

Co-authorship network of co-authors of Lee A. Albacker

This figure shows the co-authorship network connecting the top 25 collaborators of Lee A. Albacker. A scholar is included among the top collaborators of Lee A. Albacker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lee A. Albacker. Lee A. Albacker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). 2024 ·Journal of Clinical Oncology ·Arun Azad,Karim Fizazi,Douglas Laird,Nobuaki Matsubara,Ugo De Giorgi,Consuelo Buttigliero,Lawrence I. Karsh,Jae Young Joung,Steven Yip,(unknown),Lee A. Albacker,Cynthia G. Healy,Xun Lin,Jijumon Chelliserry,Neeraj Agarwal	0
2	Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB 2023 ·Journal for ImmunoTherapy of Cancer ·Jie He,Natallia Kalinava,Parul Doshi,Dean C. Pavlick,Lee A. Albacker,Ericka M. Ebot,(unknown),James Pratt,Gina Fusaro,Geoffrey R. Oxnard,George Green,(unknown),Jonathan Baden	14
3	HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma 2023 ·JCO Precision Oncology ·Niamh Coleman,Kathrina L. Marcelo,Julia F. Hopkins,(unknown),(unknown),Lingzhi Hong,(unknown),Binaifer Balsara,Mollie Leoni,Curtis R. Pickering,Jeffrey N. Myers,John V. Heymach,Lee A. Albacker,David S. Hong,Maura L. Gillison,Xiuning Le	17
4	A pan-sarcoma landscape of telomeric content shows that alterations in RAD51B and GID4 are associated with higher telomeric content 2023 ·npj Genomic Medicine ·Radwa Sharaf,Dexter X. Jin,John P. Grady,Christine E. Napier,Ericka M. Ebot,Garrett M. Frampton,Lee A. Albacker,David M. Thomas,Meagan Montesion	5
5	Mutations in the TERC template sequence can be incorporated into the telomeres of human tumors 2022 ·PLoS ONE ·Radwa Sharaf,Garrett M. Frampton,Lee A. Albacker	2
6	Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling 2022 ·Journal of Molecular Diagnostics ·Ian M. Silverman,Meijuan Li,Karthikeyan Murugesan,Melanie A. Krook,Milind Javle,Robin Kate Kelley,Mitesh J. Borad,Sameek Roychowdhury,Wei Meng,Bahar Yilmazel,(unknown),(unknown),Luis Féliz,Timothy C. Burn,Lee A. Albacker	8
7	Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy 2022 ·npj Precision Oncology ·Ericka M. Ebot,Daniel Duncan,Khaled Tolba,David Fabrizio,Garrett M. Frampton,Leah A. Comment,Lee A. Albacker	15
8	FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas 2021 ·Neuro-Oncology Advances ·Radwa Sharaf,Dean C. Pavlick,Garrett M. Frampton,Maureen Cooper,(unknown),Natalie Danziger,James Haberberger,Brian M. Alexander,Timothy F. Cloughesy,William H. Yong,Linda M. Liau,Phioanh L. Nghiemphu,(unknown),Albert Lai,Shakti Ramkissoon,Lee A. Albacker	4
9	Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression 2021 ·Journal for ImmunoTherapy of Cancer ·Richard S.P. Huang,Karthikeyan Murugesan,Meagan Montesion,Dean C. Pavlick,Douglas A. Mata,Matthew Hiemenz,Brennan Decker,Garrett M. Frampton,Lee A. Albacker,Jeffrey S. Ross	16
10	Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma 2021 ·JCO Precision Oncology ·Karthikeyan Murugesan,Radwa Sharaf,Meagan Montesion,Jay A. Moore,(unknown),Dean C. Pavlick,Garrett M. Frampton,Vivek Upadhyay,Brian M. Alexander,Vincent A. Miller,Milind Javle,Tanios Bekaii‐Saab,Lee A. Albacker,Jeffrey S. Ross,Siraj M. Ali	12
11	CDKN2C -Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53 / RB1 –Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-Codeletion 2020 ·JCO Precision Oncology ·Erik A. Williams,Radwa Sharaf,Brennan Decker,(unknown),(unknown),Meagan Montesion,Ethan S. Sokol,Dean C. Pavlick,(unknown),Kevin Jon Williams,Jeffrey M. Venstrom,Brian M. Alexander,Jeffrey S. Ross,Lee A. Albacker,Douglas I. Lin,Shakti Ramkissoon,Julia A. Elvin	10
12	The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy 2019 ·Clinical Cancer Research ·Todd C. Knepper,Meagan Montesion,Jeffery S. Russell,Ethan S. Sokol,Garrett M. Frampton,Vincent A. Miller,Lee A. Albacker,Howard L. McLeod,Zeynep Eroglu,Nikhil I. Khushalani,Vernon K. Sondak,Jane L. Messina,Michael J. Schell,James A. DeCaprio,Kenneth Y. Tsai,Andrew S. Brohl	111
13	PD-L1 expression and tumor mutational burden are independent biomarkers in most cancersbreakdown → 2019 ·JCI Insight ·Mark Yarchoan,Lee A. Albacker,Alexander C. Hopkins,Meagan Montesion,Karthikeyan Murugesan,Teena Vithayathil,Neeha Zaidi,Nilofer S. Azad,Daniel A. Laheru,Garrett M. Frampton,Elizabeth M. Jaffee	386
14	Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC 2018 ·PLoS ONE ·Michael E. Goldberg,Meagan Montesion,Lauren Young,James Suh,Joel Greenbowe,Mark Kennedy,Giuseppe Giaccone,Wallace Akerley,Afshin Dowlati,Ben Creelan,J. Kevin Hicks,Paul J. Hesketh,Karen Kelly,Jonathan W. Riess,Vincent A. Miller,Philip J. Stephens,Garrett M. Frampton,Siraj M. Ali,Jeffrey P. Gregg,Lee A. Albacker	15
15	High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis 2017 ·Cancer Research ·Ryan J. Hartmaier,Lee A. Albacker,Juliann Chmielecki,Mark Bailey,Jie He,Michael E. Goldberg,Shakti Ramkissoon,James Suh,Julia A. Elvin,(unknown),Garrett M. Frampton,Jeffrey S. Ross,Vincent A. Miller,Philip J. Stephens,Doron Lipson	85
16	Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion 2017 ·PLoS ONE ·Lee A. Albacker,Jeremy Wu,Peter Smith,Markus Warmuth,Philip J. Stephens,Ping Zhu,Lihua Yu,Juliann Chmielecki	83
17	Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity 2011 ·Journal of Allergy and Clinical Immunology ·Hye Young Kim,Ya‐Jen Chang,Srividya Subramanian,Hyun-Hee Lee,Lee A. Albacker,Ponpan Matangkasombut,Paul B. Savage,Andrew N. J. McKenzie,Dirk E. Smith,James B. Rottman,Rosemarie H. DeKruyff,Dale T. Umetsu	265
18	Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunitybreakdown → 2011 ·Nature Immunology ·Ya‐Jen Chang,Hye Young Kim,Lee A. Albacker,Nicole Baumgarth,Andrew N. J. McKenzie,Dirk E. Smith,Rosemarie H. DeKruyff,Dale T. Umetsu	640
19	Epithelium 2009 ·Mucosal Immunology ·Carmen Alonso,Bayasi Guleng,Seiji Arihiro,Agnès Gardet,(unknown),Daniel K. Podolsky,Hans‐Christian Reinecker,Muriel Pichavant,Hye Young Kim,Ponpan Matangkasombut,Lee A. Albacker,Everett Meyer,Rosemarie H. DeKruyff,Dale T. Umetsu,(unknown),Eric Rogier,Finn–Eirik Johansen,Charlotte S. Kaetzel	0
20	Tissue expression of PD-L1 mediates peripheral T cell tolerancebreakdown → 2006 ·The Journal of Experimental Medicine ·Mary Keir,Spencer C. Liang,Indira Guleria,Yvette Latchman,Andi Qipo,Lee A. Albacker,Maria Koulmanda,Gordon J. Freeman,Mohamed H. Sayegh,Arlene H. Sharpe	1010

About Lee A. Albacker

Lee A. Albacker is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 89 papers that have together received 3.7k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (38 papers), Lung Cancer Treatments and Mutations (22 papers) and Cancer Immunotherapy and Biomarkers (18 papers). The work is most often cited by research in Immunology (1.9k citations), Oncology (1.6k citations) and Cancer Research (451 citations). Lee A. Albacker has collaborated with scholars based in United States, Italy and United Kingdom. Frequent co-authors include Dale T. Umetsu, Rosemarie H. DeKruyff, Ya‐Jen Chang, Hye Young Kim, Gordon J. Freeman, Andrew N. J. McKenzie, Dirk E. Smith, Yvette Latchman, Maria Koulmanda and Spencer C. Liang. Their work appears in journals such as Journal of Biological Chemistry, Nature Medicine and The Journal of Experimental Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact